ArticleEuropean journal of neurology2025
Applicability and Correlates of a Symptom-Led Staging System for Primary Progressive Aphasia.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Staging Language-Led Neurodegenerative Diseases in a Language-Based World: The Challenge of the PPA-Squared Scale.European journal of neurology · 2026Article
- Applicability and Correlates of a Symptom-Led Staging System for Primary Progressive Aphasia.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aimed at assessing the applicability of a symptom-led staging system for primary progressive aphasia (PPA) based on retrospective medical records, as well as at exploring their demographic and clinical correlates.
methods75 PPA patients (10 semantic, 28 non-fluent, 22 logopenic, and 16 mixed variants) were retrospectively staged according to the PPA Progression Planning Aid (PPA-Squared) system, which stages the disease by accounting for clinical features along three axes: (1) Communication; (2) Non-Verbal Thinking and Personality; (3) Personal Care and Well-Being. The percentage of successfully staged patients was computed. The association between PPA-Squared scores and demographic and clinical data was tested via non-parametric tests. The predictive capability of PPA-Squared scores towards survival was explored via a Mantel-Cox test.
results89.3% of patients were successfully staged based on retrospective medical records. The PPA-Squared was associated with the MMSE (p < 0.001), ADL (p = 0.021), and IADL scores (p < 0.001) and a set of second-level cognitive measures tapping on attention, executive functions, language, long-term memory, and visuo-spatial abilities (p ≤ 0.049). No association was found between the PPA-Squared and demographic features, symptom duration, PPA phenotype, the presence of motor involvement, and survival. DISCUSSION: The PPA-Squared is a feasible and clinically valid tool for staging PPA patients based on their cognitive and functional status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.